Document is current
Any future updates will be listed below
-
Authors
Sujit, Sheeba J. https://orcid.org/0000-0001-8302-7046
Aminu, Muhammad https://orcid.org/0000-0002-9903-8812
Karpinets, Tatiana V.
Chen, Pingjun https://orcid.org/0000-0003-0528-1713
Saad, Maliazurina B.
Salehjahromi, Morteza
Boom, John D. https://orcid.org/0009-0004-6625-318X
Qayati, Mohamed
George, James M. https://orcid.org/0000-0002-9723-6444
Allen, Haley
Antonoff, Mara B. https://orcid.org/0000-0001-6247-9537
Hong, Lingzhi https://orcid.org/0000-0001-6553-3279
Hu, Xin
Heeke, Simon https://orcid.org/0000-0002-5916-534X
Tran, Hai T.
Le, Xiuning https://orcid.org/0000-0002-8554-1185
Elamin, Yasir Y. https://orcid.org/0000-0002-5312-909X
Altan, Mehmet https://orcid.org/0000-0001-9229-156X
Vokes, Natalie I. https://orcid.org/0000-0002-3766-5335
Sheshadri, Ajay https://orcid.org/0000-0002-8091-0180
Lin, Julie
Zhang, Jianhua https://orcid.org/0000-0001-5412-9860
Lu, Yang https://orcid.org/0000-0001-9571-4679
Behrens, Carmen
Godoy, Myrna C. B.
Wu, Carol C. https://orcid.org/0000-0003-1005-0995
Chang, Joe Y.
Chung, Caroline
Jaffray, David A.
Wistuba, Ignacio I.
Lee, J. Jack https://orcid.org/0000-0001-5469-9214
Vaporciyan, Ara A.
Gibbons, Don L. https://orcid.org/0000-0003-2362-3094
Heymach, John https://orcid.org/0000-0001-9068-8942
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
Cascone, Tina https://orcid.org/0000-0003-3008-5407
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R00CA218667, R01CA262425, R01CA276178)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 27 June 2023
Accepted: 21 March 2024
First Online: 11 April 2024
Competing interests
: X.L. reports Consulting/advisory fees from Eli Lilly, EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Regeneron, Boehringer Ingelheim, Hengrui Therapeutics, Bayer, Teligene, Taiho, Daiichi Sankyo, Janssen, Blueprint Medicines, Sensei Biotherapeutics, SystImmune, ArriVent, Abion, and Abbvie Research Funding to Institution from Eli Lilly, EMD Serono, ArriVent, Dizal, Teligene, Regeneron, Janssen, ThermoFisher, Takeda, and Boehringer Ingelheim. Travel Support from EMD Serono, Janssen, and Spectrum Pharmaceutics. Stock options from BlossomHill. T.C. reports speaker fees and honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; having an advisory role or receiving consulting fees from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co, Genentech, and Arrowhead Pharmaceuticals; and institutional research funding from AstraZeneca, Bristol Myers Squibb, and EMD Serono. N.I.V. receives consulting fees from Sanofi, Regeneron, Oncocyte, and Eli Lilly; and research funding from Mirati outside the submitted work. J.Y.C. reports research funding from BMS-MDACC, Siemens Healthcare, and consultation fees from Legion Healthcare Partners. L.Y. has grant support from Lantheus Inc. M.C.B.G. has received research funding from Siemens Healthcare. I.W. has received honoraria from Genentech/Roche, Astra Zeneca, Merck, Guardant Health, Flame, Novartis, Sanofi, Daiichi Sankyo, Dava Oncology, Amgen, GlaxoSmithKline, HTG Molecular, Jansen, Merus, Imagene, G1 Therapeutics, Abbvie, Catalyst Therapeutics, Genzyme, Regeneron, Oncocyte, Medscape, Platform Health, Pfizer, Physicians’ Education Resource, HPM Education, and Aptitute Health; Additionally, I.W. has received research support from Genentech, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya. D.L.G. has served on scientific advisory committees for Menarini Ricerche, 4D Pharma, Onconova, and Eli Lilly and has received research support from Takeda, Astellas, NGM Biopharmaceuticals, Boehringer Ingelheim and AstraZeneca. J.V.H. reports being on scientific advisory boards for AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, and Janssen Global Services; receiving research support from AstraZeneca, Takeda, Boehringer Ingelheim, and Spectrum; and receiving licensing fees from Spectrum. C.C.W reports research support from the Medical Imaging and Data Resource Center from NIBIB/University of Chicago and royalties from Elsevier. J.Z. reports serving on the consulting/advisory board of Bristol-Myers Squibb, AstraZeneca, Novartis, Johnson & Johnson, GenePlus, Innovent, Varian, and Catalyst; receiving research grants to institutions from Merck, Novartis, and Johnson & Johnson. J.W. reports research funding from Siemens Healthcare. The remaining authors declare no competing interests.
